Medical research

T.D. Jakes Hosts Conversation with COVID-19 Vaccine Scientists

Thursday, January 21, 2021 - 5:25pm

In an effort to better inform and enlighten the public about the COVID-19 vaccine, global spiritual leader Bishop T.D.

Key Points: 
  • In an effort to better inform and enlighten the public about the COVID-19 vaccine, global spiritual leader Bishop T.D.
  • Jakes has brought together several of the world's leading coronavirus experts, including Dr. Anthony Fauci, the nation's top infectious disease official, for a panel discussion titled Conversations with America: Understanding the COVID-19 Vaccine.
  • Corbett leads the team of scientists behind the Moderna Inc. COVID-19 vaccine.
  • Jakes YouTube channel on Monday, Jan. 25, at noon CT.
    "There are many hurdles to finding a solution to the pandemic, including the supply and distribution of the vaccine," saidJakes.

Moderna Announces First Participant Dosed in Phase 1/2 Study of Moderna COVID-19 Vaccine in Japan Led by Takeda

Thursday, January 21, 2021 - 2:00pm

(Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the first participant has been dosed in the Phase 1/2 study of Modernas vaccine candidate against COVID-19 (mRNA-1273 or TAK-919) in Japan, led by Takeda Pharmaceutical Co., Ltd (NYSE: TAK).

Key Points: 
  • (Nasdaq: MRNA), a biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines, today announced that the first participant has been dosed in the Phase 1/2 study of Modernas vaccine candidate against COVID-19 (mRNA-1273 or TAK-919) in Japan, led by Takeda Pharmaceutical Co., Ltd (NYSE: TAK).
  • We are pleased that this Phase 1/2 study of our COVID-19 vaccine in healthy adults in Japan has begun.
  • This placebo-controlled Phase 1/2 study will evaluate the safety and immunogenicity of two vaccinations of mRNA-1273 given 28 days apart.
  • Takeda and Moderna previously announced that Takeda will import and distribute 50 million doses of Modernas COVID-19 vaccine candidate starting in the first half of 2021, pending licensure in Japan.

New Administration and Congress Must Act Quickly to Protect Older Americans from Resurgent COVID-19 Pandemic

Thursday, January 21, 2021 - 2:00pm

It has created an even greater urgency to enact solutions now that enable every American to age with health, security, and dignity."

Key Points: 
  • It has created an even greater urgency to enact solutions now that enable every American to age with health, security, and dignity."
  • NCOA supports President Biden's COVID-19 vaccine goal to administer 100 million doses in the first 100 days of his Administration.
  • While demand for these services has increased, Older Americans Act programs received only modest funding increases this fiscal year, and much more is needed.
  • "We know there are solutions, and we look forward to working with the new Administration and Congress to make them a reality."

HCAP Partners Announces New Investment in 83bar

Thursday, January 21, 2021 - 1:51pm

Founded in 2015, 83bar provides a cost-effective patient activation platform to find and retain qualified individuals for clinical trials and commercial clients.

Key Points: 
  • Founded in 2015, 83bar provides a cost-effective patient activation platform to find and retain qualified individuals for clinical trials and commercial clients.
  • Their investment will help us continue our rapid growth as we help more healthcare companies manage their patients' journeys", stated 83bar Managing Partner Dan Maynard.
  • Nicolas Lopez, Principal at HCAP Partners, commented, "As a leader in patient journey management, we are bullish on 83bar's ambitious growth plans.
  • To find out how 83bar can help your medical device, medical diagnostic, or clinical trial, visit us at www.83bar.com .

BetterLife Selects CRO to Conduct Clinical Trials for AP-003 in COVID-19 Cases in Indonesia

Thursday, January 21, 2021 - 1:30pm

Jakarta-based Equilab ( http://www.equilab-int.com ) is an internationally recognized CRO with a strong team of clinical and analytical researchers that have already conducted clinical trials in COVID-19 patients.

Key Points: 
  • Jakarta-based Equilab ( http://www.equilab-int.com ) is an internationally recognized CRO with a strong team of clinical and analytical researchers that have already conducted clinical trials in COVID-19 patients.
  • BetterLife and Equilab will conduct the placebo-controlled blinded trials in COVID-19 patients at Equilabs own 75 bed clinical facility.
  • We changed the site of our proposed AP-003 clinical trials in COVID-19 patients from Australia to Indonesia.
  • Established in 2002, Equilab is one of the leading Contract Research Organisations (CRO) in Indonesia that provides full-service clinical research for global and local clients.

EuBiologics Gets an IND Approval for Phase I/II Clinical Trial of 'EuCorVac-19' in Korea

Thursday, January 21, 2021 - 1:00pm

EuBiologics (KOSDAQ: 206650), a South Korean biotech company, announced on Jan 21st that EuCorVac-19, a COVID-19 vaccine candidate developed by EuBiologics, was approved to conduct Phase I/II clinical trials by the Ministry of Food and Drug Safety, immediately entering into the Phase I trial.

Key Points: 
  • EuBiologics (KOSDAQ: 206650), a South Korean biotech company, announced on Jan 21st that EuCorVac-19, a COVID-19 vaccine candidate developed by EuBiologics, was approved to conduct Phase I/II clinical trials by the Ministry of Food and Drug Safety, immediately entering into the Phase I trial.
  • View the full release here: https://www.businesswire.com/news/home/20210121005311/en/
    EuBiologics (KOSDAQ: 206650) got an IND approval for Phase I/II clinical trial of a COVID-19 vaccine candidate EuCorVac-19 in Korea, immediately entering into the Phase I trial.
  • The EuCorVac-19 under development is a safe vaccine formulated with the coronavirus spike protein using recombinant protein technology and with a potent adjuvant.
  • EuBiologics also has a GMP accredited facility which can manufacture recombinant protein antigens and adjuvants, with confidence to provide competitive pricing.

VBI Vaccines Announces Progress of Coronavirus Vaccine Program

Thursday, January 21, 2021 - 1:00pm

VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today provided an update on the progress of its coronavirus vaccine program, consisting of two vaccine candidates: (1) VBI-2901, a trivalent pan-coronavirus vaccine candidate expressing the SARS-CoV-2 (COVID-19), SARS-CoV (SARS), and MERS-CoV (MERS) spike proteins; and (2) VBI-2902, a monovalent vaccine candidate expressing the SARS-CoV-2 spike protein.

Key Points: 
  • VBI Vaccines Inc. (Nasdaq: VBIV) (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, today provided an update on the progress of its coronavirus vaccine program, consisting of two vaccine candidates: (1) VBI-2901, a trivalent pan-coronavirus vaccine candidate expressing the SARS-CoV-2 (COVID-19), SARS-CoV (SARS), and MERS-CoV (MERS) spike proteins; and (2) VBI-2902, a monovalent vaccine candidate expressing the SARS-CoV-2 spike protein.
  • VBI Vaccines Inc. ( Nasdaq: VBIV ) is a commercial-stage biopharmaceutical company developing a next generation of vaccines to address unmet needs in infectious disease and immuno-oncology.
  • VBIs lead eVLP programs include a vaccine immunotherapeutic candidate targeting glioblastoma (GBM), a prophylactic cytomegalovirus (CMV) vaccine candidate, and a prophylactic coronavirus vaccine program.
  • VBI is headquartered in Cambridge, MA, with research operations in Ottawa, Canada, and research and manufacturing facilities in Rehovot, Israel.

Science 37® Launches 'Science 37 Certified'--a Partnership Program Enabling CROs to Effectively Execute Decentralized Clinical Trials

Thursday, January 21, 2021 - 12:55pm

LOS ANGELES, Jan. 21, 2021 /PRNewswire/ -- Science 37, the industry leader in decentralized clinical trials, today announced a premier partnership program, Science 37 Certified, designed to empower CROs with access, training, and commercial support required to successfully deliver decentralized clinical studies for pharmaceutical sponsors.

Key Points: 
  • LOS ANGELES, Jan. 21, 2021 /PRNewswire/ -- Science 37, the industry leader in decentralized clinical trials, today announced a premier partnership program, Science 37 Certified, designed to empower CROs with access, training, and commercial support required to successfully deliver decentralized clinical studies for pharmaceutical sponsors.
  • "As the clinical trial model becomes more dependent on decentralized methodologies to connect patients and providers, many CROs need to rapidly bolster their operations accordingly to compete," said David Coman, CEO of Science 37.
  • "As the leader in decentralized clinical trials (DCT), we've built the most advanced Operating System of technology and services to enable decentralization.
  • To learn more about applying for the globally available Science 37 Certified program, CROs should email Science 37 at Partners@science37.com
    Science 37 is making the promise of virtual trials the new reality.

XClinical to Merge with Carenity and Fortress Medical Systems Forming a New Data Science Company Serving Life Science Markets Worldwide

Thursday, January 21, 2021 - 1:00pm

Together, the three businesses will form a new, innovative data science company, powered by cutting edge technology.

Key Points: 
  • Together, the three businesses will form a new, innovative data science company, powered by cutting edge technology.
  • XClinical, a leading international provider of eClinical software solutions, has been the first acquisition in BID Equitys Life Sciences portfolio.
  • Through its award-winning platform and data science expertise, Carenity provides direct, timely and compliant access to patient real-world data.
  • Fortress Medical Systems was founded in 1997 with the launch of Clindex, one of the first integrated software systems designed for clinical trials.

AriBio Co., Ltd. Announces Last Patient Last Visit in Phase 2 Clinical Trial of AR1001 in Mild to Moderate Alzheimer’s Patients

Thursday, January 21, 2021 - 10:14am

AR1001 is a first-in-class, orally dosed investigational drug for mild to moderate Alzheimers disease.

Key Points: 
  • AR1001 is a first-in-class, orally dosed investigational drug for mild to moderate Alzheimers disease.
  • Despite the challenges presented by the COVID-19 pandemic, we were able to complete dosing and follow-up assessments in this trial.
  • AriBio is the first company from South Korea to successfully complete a Phase 2 study for Alzheimers disease in the United States.
  • AR1001-ADP2-US01 (NCT03625622) is A Double-Blind, Randomized and Placebo-Controlled Study to Evaluate Efficacy and Safety of 26-Week Treatment of AR1001 in Patients with Mild to Moderate Alzheimer's disease.